Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women’s Health Initiative randomized trials

JAMA - Journal of the American Medical Association

Volumn 318, Issue 10, 2017, Pages 927-938

  Manson, JoAnn E ^a   Aragaki, Aaron K ^b   Rossouw, Jacques E ^c   Anderson, Garnet L ^b   Prentice, Ross L ^b   LaCroix, Andrea Z ^d   Chlebowski, Rowan T ^e,f   Howard, Barbara V ^g,h   Thomson, Cynthia A ⁱ   Margolis, Karen L ^j   Lewis, Cora E ^k   Stefanick, Marcia L ^l   Jackson, Rebecca D ^m   Johnson, Karen C ⁿ   Martin, Lisa W ^o   Shumaker, Sally A ^p   Espeland, Mark A ^p   Wactawski Wende, Jean ^q  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b USA   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g MEDSTAR RESEARCH INSTITUTE   (United States)

^h Delaware   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j HEALTHPARTNERS INSTITUTE   (United States)

^k University of Alabama at Birmingham   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^o GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^p WAKE FOREST SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE; PLACEBO;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CAUCASIAN; CAUSE SPECIFIC MORTALITY; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MORTALITY; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; UNITED STATES; WOMEN'S HEALTH; ADVERSE EFFECTS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; RISK;

AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; MORTALITY; NEOPLASMS; POSTMENOPAUSE; RISK;

EID: 85029557031     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.11217     Document Type: Article

References (39)

1. The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials. 1998; 19(1):61-109.
2. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3): 321-333.
3. Anderson GL, Limacher M, Assaf AR, et al; Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
4. Heiss G, Wallace R, Anderson GL, et al; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-1045.
5. LaCroix AZ, Chlebowski RT, Manson JE, et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305 (13):1305-1314.
6. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13): 1353-1368.
7. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477.
8. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994;140(11):1016-1019.
9. Manson JE, Shufelt CL, Robins JM. The potential for postrandomization confounding in randomized cinical trials. JAMA. 2016;315(21):2273-2274.
10. Shumaker SA, Legault C, Rapp SR, et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289 (20):2651-2662.
11. Shumaker SA, Legault C, Kuller L, et al; Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291(24):2947-2958.
12. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Health Statistics. Deaths: Final Data for 2013. National Vital Statistics Report. Vol 64, No. 2. http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_02.pdf. Accessed July 22, 2016.
13. Margolis KL, Bonds DE, Rodabough RJ, et al; Women’s Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004;47(7):1175-1187.
14. Bonds DE, Lasser N, Qi L, et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women’s Health Initiative randomised trial. Diabetologia. 2006;49(3):459-468.
15. Reijmer YD, van den Berg E, de Bresser J, et al; Utrecht Diabetic Encephalopathy Study Group. Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors. Diabetes Metab Res Rev. 2011;27(2):195-202.
16. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004;35(11)(suppl 1):2620-2622.
17. North American Menopause Society. The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause. 2012;19(3):257-271.
18. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.
19. Goodman NFCR, Cobin RH, Ginzburg SB, Katz IA, Woode DE; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract. 2011;17(suppl 6):1-25.
20. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005;293(3):330-339.
21. Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935-948.
22. Sarrel P, Portman D, Lefebvre P, et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2015;22(3):260-266.
23. Manson JE, Kaunitz AM. Menopause management-getting clinical care back on track. N Engl J Med. 2016;374(9):803-806.
24. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-613.
25. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336(25):1769-1775.
26. Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality: preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA. 1983;249(7):903-906.
27. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151(1):75-78.
28. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995; 85(8 pt 1):1128-1132.
29. Santen RJ, Allred DC, Ardoin SP, et al; Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7)(suppl 1):s1-s66.
30. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308(5728):1583-1587.
31. Writing Group on behalf of Workshop Consensus Group. Aging, menopause, cardiovascular disease and HRT: International Menopause Society Consensus Statement. Climacteric. 2009;12(5):368-377.
32. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53(3):605-619.
33. Hodis HN, Mack WJ, Henderson VW, et al; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with Estradiol. N Engl J Med. 2016;374(13):1221-1231.
34. Chlebowski RT, Kuller LH, Prentice RL, et al; WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573-587.
35. Stefanick ML, Anderson GL, Margolis KL, et al; WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647-1657.
36. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486.
37. Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women’s Health Initiative randomized clinical trials. JAMA Oncol. 2015;1(3):296-305.
38. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34(1):130-162.
39. Chlebowski RT, Anderson GL, Sarto GE, et al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women’s Health Initiative Randomized Trial. J Natl Cancer Inst. 2015;108(3):djv350.